Mallinckrodt PLC (NYSE:MNK) has received a consensus recommendation of “Hold” from the twenty-two ratings firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $39.52.

Several equities analysts have recently weighed in on the company. Barclays downgraded Mallinckrodt from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $23.00 to $20.00 in a research report on Friday, February 2nd. ValuEngine downgraded Mallinckrodt from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Mallinckrodt from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Mizuho reaffirmed a “neutral” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Mallinckrodt in a research report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $42.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research report on Monday, January 8th.

In other Mallinckrodt news, Director Dr Kneeland Youngblood acquired 4,560 shares of the business’s stock in a transaction on Tuesday, November 28th. The shares were bought at an average price of $21.94 per share, with a total value of $100,046.40. Following the transaction, the director now directly owns 19,789 shares of the company’s stock, valued at approximately $434,170.66. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.53% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of MNK. Arrowstreet Capital Limited Partnership bought a new position in shares of Mallinckrodt during the 4th quarter worth $30,563,000. Schroder Investment Management Group grew its position in shares of Mallinckrodt by 5,506.0% during the 4th quarter. Schroder Investment Management Group now owns 1,121,200 shares of the company’s stock worth $25,294,000 after buying an additional 1,101,200 shares in the last quarter. Prudential Financial Inc. grew its position in shares of Mallinckrodt by 114.9% during the 3rd quarter. Prudential Financial Inc. now owns 1,379,978 shares of the company’s stock worth $51,569,000 after buying an additional 737,791 shares in the last quarter. LSV Asset Management grew its position in shares of Mallinckrodt by 24.8% during the 4th quarter. LSV Asset Management now owns 2,621,917 shares of the company’s stock worth $59,150,000 after buying an additional 520,697 shares in the last quarter. Finally, Spark Investment Management LLC bought a new position in shares of Mallinckrodt during the 4th quarter worth $11,356,000. 97.38% of the stock is currently owned by institutional investors and hedge funds.

Mallinckrodt (NYSE:MNK) opened at $15.96 on Wednesday. The firm has a market capitalization of $1,567.58, a P/E ratio of 2.23, a PEG ratio of 0.31 and a beta of 1.04. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08. Mallinckrodt has a 12-month low of $15.27 and a 12-month high of $55.32.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/mallinckrodt-plc-mnk-given-average-recommendation-of-hold-by-brokerages/1865120.html.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.